INT1501

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1978
Last Reported 1994
Negated 0
Speculated 0
Reported most in Abstract
Documents 13
Total Number 14
Disease Relevance 1.12
Pain Relevance 3.49

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Mention Frequency
plasma 6
pituitary gland 1
GH1 (Canis lupus)
Pain Term Frequency Confidence Heat
agonist 6 100.00 Very High Very High Very High
Clonidine 48 100.00 Very High Very High Very High
Somatostatin 5 93.44 High High
Spinal cord 2 84.28 Quite High
Disease Term Frequency Confidence Heat
Cancer 5 99.96 Very High Very High Very High
Pressure Volume 2 Under Development 1 96.92 Very High Very High Very High
Diabetes Mellitus 2 95.24 Very High Very High Very High
Impaired Glucose Tolerance 2 90.24 High High
Hyperinsulinism 2 86.96 High High
Spinal Cord Injury 1 75.00 Quite High
Dwarfism 1 60.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The recently discovered local production of GH probably played a role in mammary tumorigenesis.
Gene_expression (production) of GH
1) Confidence 0.58 Published 1994 Journal Eur. J. Endocrinol. Section Abstract Doc Link 7921231 Disease Relevance 0.37 Pain Relevance 0.10
Chronic overproduction of growth hormone in man and the cat is most often caused by a GH-producing tumour of the pituitary gland.
Gene_expression (producing) of GH in pituitary gland associated with cancer
2) Confidence 0.54 Published 1991 Journal Acta Endocrinol. Section Abstract Doc Link 1839344 Disease Relevance 0.10 Pain Relevance 0.09
For a better understanding of the mechanism of progestin-induced GH synthesis and secretion, studies were carried out in healthy dogs and in dogs presented with GH excess.
Gene_expression (synthesis) of GH
3) Confidence 0.54 Published 1991 Journal Acta Endocrinol. Section Abstract Doc Link 1839344 Disease Relevance 0.09 Pain Relevance 0.20
In female dogs with experimental or spontaneous progestin-induced chronic overproduction of GH (and IGF-I), plasma GH levels were completely unresponsive to stimulation with hGHRH and clonidine and to inhibition with SMS 201-995.
Gene_expression (overproduction) of GH in plasma associated with clonidine
4) Confidence 0.47 Published 1991 Journal Acta Endocrinol. Section Abstract Doc Link 1839344 Disease Relevance 0.06 Pain Relevance 0.40
After cessation of progestin administration, basal plasma levels of GH and IGF-I did not return to pretreatment values.
Gene_expression (levels) of GH in plasma
5) Confidence 0.45 Published 1994 Journal Eur. J. Endocrinol. Section Abstract Doc Link 7921231 Disease Relevance 0.27 Pain Relevance 0.13
The oestradiol-MPA induced GH overproduction is associated with a reduced responsiveness of GH to clonidine and is not accompanied by GH responsiveness to TRH.
Gene_expression (overproduction) of GH associated with clonidine
6) Confidence 0.35 Published 1987 Journal Acta Endocrinol. Section Abstract Doc Link 2950711 Disease Relevance 0 Pain Relevance 0.18
MPA treatment after oestradiol implantation resulted in significantly elevated basal GH levels in all dogs, with a continuing increase in one dog.
Gene_expression (levels) of GH
7) Confidence 0.35 Published 1987 Journal Acta Endocrinol. Section Abstract Doc Link 2950711 Disease Relevance 0 Pain Relevance 0.08
On the other hand, administration of the alpha-2 adrenergic agonist clonidine (4 micrograms/kg i.v.) increased basal plasma GH levels without affecting GH responses to GHRP-6.
Gene_expression (levels) of GH in plasma associated with agonist and clonidine
8) Confidence 0.26 Published 1993 Journal J. Endocrinol. Section Abstract Doc Link 8228729 Disease Relevance 0 Pain Relevance 0.19
In adult Beagle dogs (n = 10), GHRP-6 (90 micrograms i.v.) increased basal GH levels from 2.6 +/- 1.5 to 14.4 +/- 3.1 micrograms/l (mean +/- S.E.M.) after 15 min.
Gene_expression (levels) of GH
9) Confidence 0.26 Published 1993 Journal J. Endocrinol. Section Abstract Doc Link 8228729 Disease Relevance 0 Pain Relevance 0.04
GH deficiency was evidenced in all dogs by an absence of increase in GH levels in response to clonidine administration.
Gene_expression (levels) of GH associated with clonidine
10) Confidence 0.19 Published 1984 Journal Acta Endocrinol. Section Abstract Doc Link 6322493 Disease Relevance 0.06 Pain Relevance 0.10
The growth hormone (GH) secretory response to varying doses (1, 5 and 25 micrograms/kg) of intravenous (i.v.) human GH releasing factor (GRF) (1-44) was measured in four, 16-month-old female dogs and compared to the GH response to placebo (vehicle solubilizing GRF) and standard clonidine test (10 micrograms/kg i.v.).
Gene_expression (response) of GH associated with clonidine
11) Confidence 0.16 Published 1989 Journal Zentralbl Veterinarmed A Section Abstract Doc Link 2521156 Disease Relevance 0 Pain Relevance 0.09
We have studied in old dogs the effects of short-term administration of growth hormone (GH)-releasing hormone (GHRH) alone or co-administered with clonidine (CLO), an alpha 2-adrenergic agonist, on the GH secretory pattern (cluster analysis), and GH responsiveness to an acute GHRH or GHRH + CLO challenge and plasma somatomedin C (SMC) levels.
Gene_expression (responsiveness) of GH in plasma associated with agonist and clonidine
12) Confidence 0.14 Published 1993 Journal Neuroendocrinology Section Abstract Doc Link 8321415 Disease Relevance 0 Pain Relevance 0.70
The ACTH response, as measured by plasma corticoids, and the growth hormone (GH) response were not significantly reduced.
Gene_expression (response) of GH in plasma
13) Confidence 0.13 Published 1978 Journal Neuroendocrinology Section Abstract Doc Link 206850 Disease Relevance 0.17 Pain Relevance 0.48
We have studied in old dogs the effects of short-term administration of growth hormone (GH)-releasing hormone (GHRH) alone or co-administered with clonidine (CLO), an alpha 2-adrenergic agonist, on the GH secretory pattern (cluster analysis), and GH responsiveness to an acute GHRH or GHRH + CLO challenge and plasma somatomedin C (SMC) levels.
Gene_expression (responsiveness) of GH in plasma associated with agonist and clonidine
14) Confidence 0.12 Published 1993 Journal Neuroendocrinology Section Abstract Doc Link 8321415 Disease Relevance 0 Pain Relevance 0.70

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox